Investigating the effect of nandrolone on the quality of life in female patients with heart failure

Abstract

Heart failure has a significant impact on the quality of life of the patient. Therefore, maintaining and improving the quality of life of patients is one of the main treatment goals in heart failure patients. The present study was conducted with the aim of investigating the effect of nandrolone on the quality of life in women with heart failure. Methods and Materials: In this single-blind clinical trial study, 90 female patients with FCII and FCIII heart failure were randomly divided into two groups of 45 people. Patients in the intervention group received nandrolone decanoate 25 mg intramuscularly once a week for one month, and the placebo group received the same amount of placebo. The quality of life in both groups was measured before the and after the intervention using Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ) and SF-36 questionnaires. Results: In the nandrolone group, the mean scores in the physical dimension, emotional dimension and the total MLHFQ score were significantly reduced compared to the placebo group. So that, the score mean changes in the physical dimension in nandrolone and placebo groups were -2.6 ± 0.5 and -0.47 ± 0.2 (p<0.001), in the emotional dimension, -3.24 ± 0.4 and -1.49 ± 0.26 (p=0.001) and in the total score, -9.91 ± 1.5 and -2.97 ± 0.61 (p<0.001) respectively. The mean changes of SF-36 total score were 15.14 ± 3.04 and 12.71 ± 1.32, respectively, which had a significant difference between the two groups (p=0.05).